CRBU

CRBU

USD

Caribou Biosciences Inc. Common Stock

$2.090+0.070 (3.465%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$2.020

最高价

$2.120

最低价

$1.930

成交量

1.29M

公司基本面

市值

194.6M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

2.19M

交易所

NMS

货币

USD

52周价格范围

最低价 $0.66当前价 $2.090最高价 $3.535

相关新闻

GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the

查看更多
Caribou Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on

查看更多
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
GlobeNewswire

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast

查看更多
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma